Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Rafael Bejar, MD PhD, Hongying Zhang, MDPhD, Nasrin Rastgoo, PhD, Khalid Benbatoul, BS, Yuying Jin, PhD, Matthew Thayer, BS., Susan Sheng, PhD, Gregory k Chow, BA, MBA, Victor Montalvo-Lugo, Jotin Marango, MD, Stephen B Howell, MD, William G Rice, PhD

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-141495

Published: 2020

Journal Articles

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-141409

Published: 2020

Journal Articles

A Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

Stephen B Howell, MD, Hongying Zhang, MD PhD, William G Rice, PhD

Blood (2019) 134 (Supplement_1): 5477.

https://doi.org/10.1182/blood-2019-130784

Published: 2019

Journal Articles

A Phase 1a/b Dose Escalation Study of Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Stephen B Howell, MD, Hongying Zhang, MD PhD, William G Rice, PhD

Blood (2019) 134 (Supplement_1): 5148.

https://doi.org/10.1182/blood-2019-129685

Published: 2019

Journal Articles

Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations

Cheng-Yu Tsai, PhD, Hongying Zhang, MD PhD, William G Rice, PhD, Stephen B Howell, MD

Blood (2019) 134 (Supplement_1): 5755.

https://doi.org/10.1182/blood-2019-123571

Published: 2019

Journal Articles

CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells

Ekaterina Kim, MS, Hongying Zhang, MD PhD, Mariela Sivina, Alicia Vaca, PhD, Philip A. Thompson, MBBS, Nitin Jain, MD, Alessandra Ferrajoli, MD, Zeev E. Estrov, MD, Michael J Keating, MBBS, William G. Wierda, MD PhD, William G Rice, PhD, Michael Andreeff, MD PhD, Jan A. Burger, MD PhD

Blood (2019) 134 (Supplement_1): 3051.

https://doi.org/10.1182/blood-2019-124473

Published: 2019

Journal Articles

Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

Mahesh Basyal, Weiguo Zhang, MD PhD, Nalini B Patel, Sujan Piya, PhD, Hongying Zhang, MD PhD, William E. Fogler, PhD, William G Rice, PhD, John L. Magnani, PhD, Gautam M. Borthakur, MD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 3802.

https://doi.org/10.1182/blood-2019-126030

Published: 2019

Journal Articles

CG'806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells

Hongying Zhang, MD, PhD, Andrea Local, PhD, Khalid Benbatoul, BS, Peter Folger, BS, Susan Sheng, PhD, Taryn McLaughlin, MS, Alexey V Danilov, MD PhD, Stephen E Kurtz, PhD, Jeffrey W. Tyner, PhD, Stephen Howell, MD, William G Rice, PhD

Blood (2018) 132 (Supplement 1): 3503.

https://doi.org/10.1182/blood-2018-99-117285

Published: 2018

Journal Articles

Concomitant Targeting of FLT3 and BTK with CG'806 Overcomes FLT3-Inhibitor Resistance through Inhibition of Autophagy

Weiguo Zhang, MD PhD, Guopan Yu, MD, PhD, Hongying Zhang, MD, PhD, Charlie Ly, BS, Bin Yuan, Vivian Ruvolo, MS, Sujan Piya, PhD, Seemana Bhattacharya, PhD, Qi Zhang, PhD, Gautam Borthakur, MD, Venkata Lokesh Battula, PhD, Marina Y. Konopleva, MD PhD, William G Rice, PhD, Michael Andreeff, MD PhD

Blood (2018) 132 (Supplement 1): 2635.

https://doi.org/10.1182/blood-2018-99-116643

Published: 2018

Journal Articles

Inhibition of c-Myc By Apto-253 As an Innovative Therapeutic Approach to Induce Cell Cycle Arrest and Apoptosis in Acute Myeloid Leukemia

Hongying Zhang, MD PhD, Andrea Local, PhD, Khalid Benbatoul, Peter Folger, Susan Sheng, PhD, Luis Esquivies, PhD, Jeff Lightfoot, PhD, Avanish Vellanki, William G. Rice, PhD

Blood (2016) 128 (22): 1716.

https://doi.org/10.1182/blood.V128.22.1716.1716

Published: 2016

Journal Articles

Mechanisms of Resistance to Apto-253

Cheng-Yu Tsai, PhD, Hongying Zhang, MD PhD, Andrea Local, PhD, William G. Rice, PhD, Stephen B Howell, MD

Blood (2016) 128 (22): 5247.

https://doi.org/10.1182/blood.V128.22.5247.5247

Published: 2016

Journal Articles

Discovery of Selective Dual Inhibitors of Bromodomain Protein BRD4 and JAK2 for Treatment of Hematologic Malignancies

Ram S. Upadhayaya, PhD, Raghava Reddy Kethiri, PhD, Avanish Vellanki, Jeff Lightfoot, PhD, Andrea Local, PhD, William G. Rice, PhD

Blood (2016) 128 (22): 5212.

https://doi.org/10.1182/blood.V128.22.5212.5212

Published: 2016

Journal Articles

Clinical Pharmacokinetics of Apto-253 Support Its Use As a Novel Agent for the Treatment of Relapsed or Refractory Hematologic Malignancies

William G. Rice, PhD, Jeff Lightfoot, PhD, Hongying Zhang, MD PhD, Tiffany Cheng, MSc, Avanish Vellanki, Robert Peralta, MSc, DVM, Stephen B Howell, MD, Andrea Local, Fannie Chau, Luis Esquivies

Blood (2015) 126 (23): 4934.

https://doi.org/10.1182/blood.V126.23.4934.4934

Published: 2015

Journal Articles

APTO-253 Induces KLF4 to Promote Potent in Vitro Pro-Apoptotic Activity in Hematologic Cancer Cell Lines and Antitumor Efficacy As a Single Agent and in Combination with Azacitidine in Animal Models of Acute Myelogenous Leukemia (AML)

William G Rice, PhD, Avanish Vellanki, MBS, MBA, Yoon Lee, PhD, Jeff Lightfoot, PhD, Robert Peralta, MSc, DVM, Mona Jamerlan, MSc, Hongnan Jin, Ronnie Lum, PhD, Tiffany Cheng, MSc

Blood (2014) 124 (21): 4813.

https://doi.org/10.1182/blood.V124.21.4813.4813

Published: 2014

Journal Articles

Inhibition of RNA Polymerase I Transcription by CX-5461 As a Therapeutic Strategy for the Cancer-Specific Activation of p53 in MLL-Rearranged Acute Myeloid Leukemias

Nadine Hein, PhD, Megan J Bywater, PhD, Kim Stanley, BSc, Inge Verbrugge, PhD, Carlene Cullinane, PhD, Adele Baker, PhD, Hannes Zuber, PhD, Amy Rappaport, PhD, Denis Drygin, PhD, Nanni Huser, PhD, Josh Bliesath, PhD, David M Ryckman, PhD, William G Rice, PhD, Scott W Lowe, PhD, Ricky W Johnstone, PhD, Richard B Pearson, PhD, Grant A. McArthur, MD, PhD, FRACP, MBBS, Ross D Hannan, PhD

Blood (2011) 118 (21): 1548.

https://doi.org/10.1182/blood.V118.21.1548.1548

Published: 2011

NARROW

A Phase 1 a/b Dose Escalation Study of the Mutation Agnostic BTK/FLT3 Inhibitor CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

A Phase 1a/b Dose Escalation Study of the MYC Repressor Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

A Phase 1 a/b Dose Escalation Trial to Evaluate the Safety and Tolerability of CG-806 in Patients with Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

A Phase 1a/b Dose Escalation Study of Apto-253 in Patients with Relapsed or Refractory AML or High-Risk MDS

Synthetic Lethal Interaction between Apto-253 and IDH1/2 Mutations

CG-806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broad Signaling Inhibition in Chronic Lymphocytic Leukemia Cells

Synergistic Targeting of BTK and E-Selectin/CXCR4 in the Microenvironment of Mantle Cell Lymphomas

CG'806, a First-in-Class Pan-FLT3/Pan-BTK Inhibitor, Exhibits Broader and Greater Potency Than Ibrutinib Against Primary and Cultured Malignant B Cells

Concomitant Targeting of FLT3 and BTK with CG'806 Overcomes FLT3-Inhibitor Resistance through Inhibition of Autophagy

Inhibition of c-Myc By Apto-253 As an Innovative Therapeutic Approach to Induce Cell Cycle Arrest and Apoptosis in Acute Myeloid Leukemia

Mechanisms of Resistance to Apto-253

Discovery of Selective Dual Inhibitors of Bromodomain Protein BRD4 and JAK2 for Treatment of Hematologic Malignancies

Clinical Pharmacokinetics of Apto-253 Support Its Use As a Novel Agent for the Treatment of Relapsed or Refractory Hematologic Malignancies

APTO-253 Induces KLF4 to Promote Potent in Vitro Pro-Apoptotic Activity in Hematologic Cancer Cell Lines and Antitumor Efficacy As a Single Agent and in Combination with Azacitidine in Animal Models of Acute Myelogenous Leukemia (AML)

Inhibition of RNA Polymerase I Transcription by CX-5461 As a Therapeutic Strategy for the Cancer-Specific Activation of p53 in MLL-Rearranged Acute Myeloid Leukemias

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only